A comparison of the effects of selective and non-selective mineralocorticoid antagonism on glucose homeostasis of heart failure patients with glucose intolerance or type II diabetes: A randomized controlled double-blind trial
Mineralocorticoid receptor antagonists (MRAs) decrease morbidity and mortality in patients with heart failure (HF). However, spironolactone, a non-selective MRA, has been shown to exert a harmful effect on glucose homeostasis. The objective of this multicenter, randomized, controlled, double-blind t...
Gespeichert in:
| Veröffentlicht in: | The American heart journal 2018-10, Vol.204, p.190-195 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 195 |
|---|---|
| container_issue | |
| container_start_page | 190 |
| container_title | The American heart journal |
| container_volume | 204 |
| creator | Korol, Sandra White, Michel O’Meara, Eileen Tournoux, François Racine, Normand Ducharme, Anique Rouleau, Jean-Lucien Liszkowski, Mark Mansour, Asmaa Jutras, Martin Guertin, Marie-Claude Bernier, Mathieu Lavoie, Joël Leclair, Grégoire Neagoe, Paul-Eduard Chaar, Diana Sirois, Martin G. de Denus, Simon |
| description | Mineralocorticoid receptor antagonists (MRAs) decrease morbidity and mortality in patients with heart failure (HF). However, spironolactone, a non-selective MRA, has been shown to exert a harmful effect on glucose homeostasis. The objective of this multicenter, randomized, controlled, double-blind trial was to compare the effects of spironolactone to those of the selective MRA eplerenone on glucose homeostasis among 62 HF patients with glucose intolerance or type II diabetes.
Trial registration number:NCT01586442. |
| doi_str_mv | 10.1016/j.ahj.2018.07.002 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2087596120</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0002870318302035</els_id><sourcerecordid>2126877152</sourcerecordid><originalsourceid>FETCH-LOGICAL-c381t-916fb81af78b726d08b3d570dde67bf380736871124700f9cc0e12427ffcd60d3</originalsourceid><addsrcrecordid>eNp9kcFuEzEQhlcIRNPCA3BBlrhw2cX2JvYGTlFFIVIlLnC2vPa4ceS1g-1tVd6WN2FCSpE4cPJ4_M0_4_mb5hWjHaNMvNt3erfvOGVDR2VHKX_SLBhdy1bI5fJps6CYagdJ-7PmvJQ9XgUfxPPmrKdIMbFcND83xKTpoLMvKZLkSN0BAefA1HK8FggY-lsgOloSU2z_ZiYfIeuQTMrVm-QtMlXfpOjLRFDtJswmFSC7NEEqVRf_W3IHOlfitA9zBnLQ1UPEZne-7h5LfKwpoHg0QFIm9f4AZLsl1usRKpT3ZEPw0abJ_wCLP4g1pxAwtGkeA7Rj8DhuzV6HF80zp0OBlw_nRfPt6uPXy8_t9ZdP28vNdWv6gdV2zYQbB6adHEbJhaXD2NuVpNaCkKPrByp7MUjG-FJS6tbGUMCYS-eMFdT2F83bk-4hp-8zlKomXwyEoCOkuShOB7laC8Ypom_-QfdpzhGnU5xx7CLZiiPFTpTJqZQMTh2yn3S-V4yqo_9qr9B_dfRfUanQbKx5_aA8jxPYx4o_hiPw4QQAruLWQ1bF4P4NWJ_RVmWT_4_8Lw7wxaQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2126877152</pqid></control><display><type>article</type><title>A comparison of the effects of selective and non-selective mineralocorticoid antagonism on glucose homeostasis of heart failure patients with glucose intolerance or type II diabetes: A randomized controlled double-blind trial</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><source>ProQuest Central UK/Ireland</source><creator>Korol, Sandra ; White, Michel ; O’Meara, Eileen ; Tournoux, François ; Racine, Normand ; Ducharme, Anique ; Rouleau, Jean-Lucien ; Liszkowski, Mark ; Mansour, Asmaa ; Jutras, Martin ; Guertin, Marie-Claude ; Bernier, Mathieu ; Lavoie, Joël ; Leclair, Grégoire ; Neagoe, Paul-Eduard ; Chaar, Diana ; Sirois, Martin G. ; de Denus, Simon</creator><creatorcontrib>Korol, Sandra ; White, Michel ; O’Meara, Eileen ; Tournoux, François ; Racine, Normand ; Ducharme, Anique ; Rouleau, Jean-Lucien ; Liszkowski, Mark ; Mansour, Asmaa ; Jutras, Martin ; Guertin, Marie-Claude ; Bernier, Mathieu ; Lavoie, Joël ; Leclair, Grégoire ; Neagoe, Paul-Eduard ; Chaar, Diana ; Sirois, Martin G. ; de Denus, Simon</creatorcontrib><description>Mineralocorticoid receptor antagonists (MRAs) decrease morbidity and mortality in patients with heart failure (HF). However, spironolactone, a non-selective MRA, has been shown to exert a harmful effect on glucose homeostasis. The objective of this multicenter, randomized, controlled, double-blind trial was to compare the effects of spironolactone to those of the selective MRA eplerenone on glucose homeostasis among 62 HF patients with glucose intolerance or type II diabetes.
Trial registration number:NCT01586442.</description><identifier>ISSN: 0002-8703</identifier><identifier>EISSN: 1097-6744</identifier><identifier>DOI: 10.1016/j.ahj.2018.07.002</identifier><identifier>PMID: 30097164</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Aged ; Biomarkers ; Biomarkers - blood ; Biomarkers - urine ; Blood Glucose - metabolism ; Blood pressure ; Diabetes ; Diabetes mellitus ; Diabetes Mellitus, Type 2 - complications ; Diuretics ; Double-Blind Method ; Double-blind studies ; Drug dosages ; Eplerenone - adverse effects ; Eplerenone - therapeutic use ; Female ; Glucose ; Glucose Intolerance - complications ; Glucose tolerance ; Glycated Hemoglobin A - metabolism ; Heart diseases ; Heart failure ; Heart Failure - blood ; Heart Failure - complications ; Heart Failure - drug therapy ; Heart Failure - physiopathology ; Homeostasis ; Humans ; Insulin ; Insulin - blood ; Insulin Resistance ; Intolerance ; Male ; Middle Aged ; Mineralocorticoid Receptor Antagonists - adverse effects ; Mineralocorticoid Receptor Antagonists - therapeutic use ; Morbidity ; Patients ; Population ; Potassium ; Prospective Studies ; Randomization ; Spironolactone - adverse effects ; Spironolactone - therapeutic use ; Stroke Volume ; Urine</subject><ispartof>The American heart journal, 2018-10, Vol.204, p.190-195</ispartof><rights>2018 Elsevier Inc.</rights><rights>Copyright © 2018 Elsevier Inc. All rights reserved.</rights><rights>2018. Elsevier Inc.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c381t-916fb81af78b726d08b3d570dde67bf380736871124700f9cc0e12427ffcd60d3</citedby><cites>FETCH-LOGICAL-c381t-916fb81af78b726d08b3d570dde67bf380736871124700f9cc0e12427ffcd60d3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.proquest.com/docview/2126877152?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>314,776,780,3536,27903,27904,64361,64363,64365,65309,72215</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30097164$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Korol, Sandra</creatorcontrib><creatorcontrib>White, Michel</creatorcontrib><creatorcontrib>O’Meara, Eileen</creatorcontrib><creatorcontrib>Tournoux, François</creatorcontrib><creatorcontrib>Racine, Normand</creatorcontrib><creatorcontrib>Ducharme, Anique</creatorcontrib><creatorcontrib>Rouleau, Jean-Lucien</creatorcontrib><creatorcontrib>Liszkowski, Mark</creatorcontrib><creatorcontrib>Mansour, Asmaa</creatorcontrib><creatorcontrib>Jutras, Martin</creatorcontrib><creatorcontrib>Guertin, Marie-Claude</creatorcontrib><creatorcontrib>Bernier, Mathieu</creatorcontrib><creatorcontrib>Lavoie, Joël</creatorcontrib><creatorcontrib>Leclair, Grégoire</creatorcontrib><creatorcontrib>Neagoe, Paul-Eduard</creatorcontrib><creatorcontrib>Chaar, Diana</creatorcontrib><creatorcontrib>Sirois, Martin G.</creatorcontrib><creatorcontrib>de Denus, Simon</creatorcontrib><title>A comparison of the effects of selective and non-selective mineralocorticoid antagonism on glucose homeostasis of heart failure patients with glucose intolerance or type II diabetes: A randomized controlled double-blind trial</title><title>The American heart journal</title><addtitle>Am Heart J</addtitle><description>Mineralocorticoid receptor antagonists (MRAs) decrease morbidity and mortality in patients with heart failure (HF). However, spironolactone, a non-selective MRA, has been shown to exert a harmful effect on glucose homeostasis. The objective of this multicenter, randomized, controlled, double-blind trial was to compare the effects of spironolactone to those of the selective MRA eplerenone on glucose homeostasis among 62 HF patients with glucose intolerance or type II diabetes.
Trial registration number:NCT01586442.</description><subject>Aged</subject><subject>Biomarkers</subject><subject>Biomarkers - blood</subject><subject>Biomarkers - urine</subject><subject>Blood Glucose - metabolism</subject><subject>Blood pressure</subject><subject>Diabetes</subject><subject>Diabetes mellitus</subject><subject>Diabetes Mellitus, Type 2 - complications</subject><subject>Diuretics</subject><subject>Double-Blind Method</subject><subject>Double-blind studies</subject><subject>Drug dosages</subject><subject>Eplerenone - adverse effects</subject><subject>Eplerenone - therapeutic use</subject><subject>Female</subject><subject>Glucose</subject><subject>Glucose Intolerance - complications</subject><subject>Glucose tolerance</subject><subject>Glycated Hemoglobin A - metabolism</subject><subject>Heart diseases</subject><subject>Heart failure</subject><subject>Heart Failure - blood</subject><subject>Heart Failure - complications</subject><subject>Heart Failure - drug therapy</subject><subject>Heart Failure - physiopathology</subject><subject>Homeostasis</subject><subject>Humans</subject><subject>Insulin</subject><subject>Insulin - blood</subject><subject>Insulin Resistance</subject><subject>Intolerance</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Mineralocorticoid Receptor Antagonists - adverse effects</subject><subject>Mineralocorticoid Receptor Antagonists - therapeutic use</subject><subject>Morbidity</subject><subject>Patients</subject><subject>Population</subject><subject>Potassium</subject><subject>Prospective Studies</subject><subject>Randomization</subject><subject>Spironolactone - adverse effects</subject><subject>Spironolactone - therapeutic use</subject><subject>Stroke Volume</subject><subject>Urine</subject><issn>0002-8703</issn><issn>1097-6744</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNp9kcFuEzEQhlcIRNPCA3BBlrhw2cX2JvYGTlFFIVIlLnC2vPa4ceS1g-1tVd6WN2FCSpE4cPJ4_M0_4_mb5hWjHaNMvNt3erfvOGVDR2VHKX_SLBhdy1bI5fJps6CYagdJ-7PmvJQ9XgUfxPPmrKdIMbFcND83xKTpoLMvKZLkSN0BAefA1HK8FggY-lsgOloSU2z_ZiYfIeuQTMrVm-QtMlXfpOjLRFDtJswmFSC7NEEqVRf_W3IHOlfitA9zBnLQ1UPEZne-7h5LfKwpoHg0QFIm9f4AZLsl1usRKpT3ZEPw0abJ_wCLP4g1pxAwtGkeA7Rj8DhuzV6HF80zp0OBlw_nRfPt6uPXy8_t9ZdP28vNdWv6gdV2zYQbB6adHEbJhaXD2NuVpNaCkKPrByp7MUjG-FJS6tbGUMCYS-eMFdT2F83bk-4hp-8zlKomXwyEoCOkuShOB7laC8Ypom_-QfdpzhGnU5xx7CLZiiPFTpTJqZQMTh2yn3S-V4yqo_9qr9B_dfRfUanQbKx5_aA8jxPYx4o_hiPw4QQAruLWQ1bF4P4NWJ_RVmWT_4_8Lw7wxaQ</recordid><startdate>201810</startdate><enddate>201810</enddate><creator>Korol, Sandra</creator><creator>White, Michel</creator><creator>O’Meara, Eileen</creator><creator>Tournoux, François</creator><creator>Racine, Normand</creator><creator>Ducharme, Anique</creator><creator>Rouleau, Jean-Lucien</creator><creator>Liszkowski, Mark</creator><creator>Mansour, Asmaa</creator><creator>Jutras, Martin</creator><creator>Guertin, Marie-Claude</creator><creator>Bernier, Mathieu</creator><creator>Lavoie, Joël</creator><creator>Leclair, Grégoire</creator><creator>Neagoe, Paul-Eduard</creator><creator>Chaar, Diana</creator><creator>Sirois, Martin G.</creator><creator>de Denus, Simon</creator><general>Elsevier Inc</general><general>Elsevier Limited</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QO</scope><scope>7RV</scope><scope>7TS</scope><scope>7X7</scope><scope>7XB</scope><scope>88C</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FD</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>201810</creationdate><title>A comparison of the effects of selective and non-selective mineralocorticoid antagonism on glucose homeostasis of heart failure patients with glucose intolerance or type II diabetes: A randomized controlled double-blind trial</title><author>Korol, Sandra ; White, Michel ; O’Meara, Eileen ; Tournoux, François ; Racine, Normand ; Ducharme, Anique ; Rouleau, Jean-Lucien ; Liszkowski, Mark ; Mansour, Asmaa ; Jutras, Martin ; Guertin, Marie-Claude ; Bernier, Mathieu ; Lavoie, Joël ; Leclair, Grégoire ; Neagoe, Paul-Eduard ; Chaar, Diana ; Sirois, Martin G. ; de Denus, Simon</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c381t-916fb81af78b726d08b3d570dde67bf380736871124700f9cc0e12427ffcd60d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Aged</topic><topic>Biomarkers</topic><topic>Biomarkers - blood</topic><topic>Biomarkers - urine</topic><topic>Blood Glucose - metabolism</topic><topic>Blood pressure</topic><topic>Diabetes</topic><topic>Diabetes mellitus</topic><topic>Diabetes Mellitus, Type 2 - complications</topic><topic>Diuretics</topic><topic>Double-Blind Method</topic><topic>Double-blind studies</topic><topic>Drug dosages</topic><topic>Eplerenone - adverse effects</topic><topic>Eplerenone - therapeutic use</topic><topic>Female</topic><topic>Glucose</topic><topic>Glucose Intolerance - complications</topic><topic>Glucose tolerance</topic><topic>Glycated Hemoglobin A - metabolism</topic><topic>Heart diseases</topic><topic>Heart failure</topic><topic>Heart Failure - blood</topic><topic>Heart Failure - complications</topic><topic>Heart Failure - drug therapy</topic><topic>Heart Failure - physiopathology</topic><topic>Homeostasis</topic><topic>Humans</topic><topic>Insulin</topic><topic>Insulin - blood</topic><topic>Insulin Resistance</topic><topic>Intolerance</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Mineralocorticoid Receptor Antagonists - adverse effects</topic><topic>Mineralocorticoid Receptor Antagonists - therapeutic use</topic><topic>Morbidity</topic><topic>Patients</topic><topic>Population</topic><topic>Potassium</topic><topic>Prospective Studies</topic><topic>Randomization</topic><topic>Spironolactone - adverse effects</topic><topic>Spironolactone - therapeutic use</topic><topic>Stroke Volume</topic><topic>Urine</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Korol, Sandra</creatorcontrib><creatorcontrib>White, Michel</creatorcontrib><creatorcontrib>O’Meara, Eileen</creatorcontrib><creatorcontrib>Tournoux, François</creatorcontrib><creatorcontrib>Racine, Normand</creatorcontrib><creatorcontrib>Ducharme, Anique</creatorcontrib><creatorcontrib>Rouleau, Jean-Lucien</creatorcontrib><creatorcontrib>Liszkowski, Mark</creatorcontrib><creatorcontrib>Mansour, Asmaa</creatorcontrib><creatorcontrib>Jutras, Martin</creatorcontrib><creatorcontrib>Guertin, Marie-Claude</creatorcontrib><creatorcontrib>Bernier, Mathieu</creatorcontrib><creatorcontrib>Lavoie, Joël</creatorcontrib><creatorcontrib>Leclair, Grégoire</creatorcontrib><creatorcontrib>Neagoe, Paul-Eduard</creatorcontrib><creatorcontrib>Chaar, Diana</creatorcontrib><creatorcontrib>Sirois, Martin G.</creatorcontrib><creatorcontrib>de Denus, Simon</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Biotechnology Research Abstracts</collection><collection>Nursing & Allied Health Database</collection><collection>Physical Education Index</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Technology Research Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>The American heart journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Korol, Sandra</au><au>White, Michel</au><au>O’Meara, Eileen</au><au>Tournoux, François</au><au>Racine, Normand</au><au>Ducharme, Anique</au><au>Rouleau, Jean-Lucien</au><au>Liszkowski, Mark</au><au>Mansour, Asmaa</au><au>Jutras, Martin</au><au>Guertin, Marie-Claude</au><au>Bernier, Mathieu</au><au>Lavoie, Joël</au><au>Leclair, Grégoire</au><au>Neagoe, Paul-Eduard</au><au>Chaar, Diana</au><au>Sirois, Martin G.</au><au>de Denus, Simon</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A comparison of the effects of selective and non-selective mineralocorticoid antagonism on glucose homeostasis of heart failure patients with glucose intolerance or type II diabetes: A randomized controlled double-blind trial</atitle><jtitle>The American heart journal</jtitle><addtitle>Am Heart J</addtitle><date>2018-10</date><risdate>2018</risdate><volume>204</volume><spage>190</spage><epage>195</epage><pages>190-195</pages><issn>0002-8703</issn><eissn>1097-6744</eissn><abstract>Mineralocorticoid receptor antagonists (MRAs) decrease morbidity and mortality in patients with heart failure (HF). However, spironolactone, a non-selective MRA, has been shown to exert a harmful effect on glucose homeostasis. The objective of this multicenter, randomized, controlled, double-blind trial was to compare the effects of spironolactone to those of the selective MRA eplerenone on glucose homeostasis among 62 HF patients with glucose intolerance or type II diabetes.
Trial registration number:NCT01586442.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>30097164</pmid><doi>10.1016/j.ahj.2018.07.002</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0002-8703 |
| ispartof | The American heart journal, 2018-10, Vol.204, p.190-195 |
| issn | 0002-8703 1097-6744 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2087596120 |
| source | MEDLINE; Elsevier ScienceDirect Journals; ProQuest Central UK/Ireland |
| subjects | Aged Biomarkers Biomarkers - blood Biomarkers - urine Blood Glucose - metabolism Blood pressure Diabetes Diabetes mellitus Diabetes Mellitus, Type 2 - complications Diuretics Double-Blind Method Double-blind studies Drug dosages Eplerenone - adverse effects Eplerenone - therapeutic use Female Glucose Glucose Intolerance - complications Glucose tolerance Glycated Hemoglobin A - metabolism Heart diseases Heart failure Heart Failure - blood Heart Failure - complications Heart Failure - drug therapy Heart Failure - physiopathology Homeostasis Humans Insulin Insulin - blood Insulin Resistance Intolerance Male Middle Aged Mineralocorticoid Receptor Antagonists - adverse effects Mineralocorticoid Receptor Antagonists - therapeutic use Morbidity Patients Population Potassium Prospective Studies Randomization Spironolactone - adverse effects Spironolactone - therapeutic use Stroke Volume Urine |
| title | A comparison of the effects of selective and non-selective mineralocorticoid antagonism on glucose homeostasis of heart failure patients with glucose intolerance or type II diabetes: A randomized controlled double-blind trial |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-26T00%3A33%3A19IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20comparison%20of%20the%20effects%20of%20selective%20and%20non-selective%20mineralocorticoid%20antagonism%20on%20glucose%20homeostasis%20of%20heart%20failure%20patients%20with%20glucose%20intolerance%20or%20type%20II%20diabetes:%20A%20randomized%20controlled%20double-blind%20trial&rft.jtitle=The%20American%20heart%20journal&rft.au=Korol,%20Sandra&rft.date=2018-10&rft.volume=204&rft.spage=190&rft.epage=195&rft.pages=190-195&rft.issn=0002-8703&rft.eissn=1097-6744&rft_id=info:doi/10.1016/j.ahj.2018.07.002&rft_dat=%3Cproquest_cross%3E2126877152%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2126877152&rft_id=info:pmid/30097164&rft_els_id=S0002870318302035&rfr_iscdi=true |